Sientra, Inc. (SIEN) |
| 0.174 -0.04 (-18.69%) 02-21 16:00 |
| Open: | 0.185 |
| High: | 0.202 |
| Low: | 0.1566 |
| Volume: | 3,327,525 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 4.937 |
| 52w Low: | 0.1566 |
Sientra, Inc. is a global medical aesthetics firm specializing in the development and distribution of a diverse range of aesthetic medical solutions. Its core offerings encompass silicone gel implants, utilized for both breast enhancement and reconstructive surgeries, alongside breast tissue expanders and various scar management solutions. These products are marketed under prominent brands such as Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. Beyond breast-related items, the company's portfolio extends to include products for body sculpting, facial and nasal implants, and saline-filled sizers. Sientra caters to a broad clientele, including hospitals, surgical facilities, plastic surgeons, dermatologists, and other specialized medical practitioners across the United States and internationally. Established in 2003, the enterprise was initially known as Juliet Medical, Inc., before adopting the Sientra, Inc. designation in April 2007. Its corporate headquarters are situated in Santa Barbara, California.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Mon, 31 Aug 2026
SIEN stock holds near recent levels as investors wait for fresh clues - AD HOC NEWS
Tue, 13 May 2025
SIEN Stock Price and Chart — TSXV:SIEN - TradingView
Wed, 28 Feb 2024
15 Countries with Most Breast Implants in the World - finance.yahoo.com
Tue, 13 Feb 2024
Breast-Implant Maker Sientra Files Bankruptcy After Consumer Pullback - Bloomberg.com
Tue, 13 Feb 2024
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - Stock Titan
Wed, 22 Mar 2023
Aziyo Biologics and Sientra Announce SimpliDerm® - globenewswire.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |